NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neoplants

Neoplants

Private
ParisHealthcare & Life Scienceshttps://neoplants.com/

Last Round

Seed

Oct 27, 2022

Total Funding Raised

$20M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Neoplants is a biotechnology company that develops bioengineered plants and their microbiomes to purify indoor air by metabolizing volatile organic compounds (VOCs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, D2C Brands, Home & Lifestyle, Subscription Commerce

Business Model

B2C

Customer Profile

Hardware + Subscription, Hardware Sales

AI Layer

Non-AI

Keywords

synbiosynthetic biologybioengineered plantsair purificationindoor air qualitynatural air purifierair purifying plantsdirect-to-consumerVOC removalD2Csubscription commercebioengineered microbiomedesigner plantsconsumable refillsgene editingbiohacking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neoplants Comparables

Compare Neoplants with similar companies based on industry and business-model similarity.

Neoplants comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Origen Air
76%
AlgenAir
75%
Vitesy
74%

Neoplants Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 27, 2022

Key People

Founding team and executive leadership

Patrick Torbey

Co-Founder & CEO

Founding Team

Thomas Renaud

Chief Financial Officer (CFO)

Executive Team

Neoplants Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased to 25, 83% of headcount.

  • Jul 6, 2026

    Open roles increased from 0 to 16, representing 57% of headcount.

Neoplants Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neoplants Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neoplants's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range30
Year Founded2018
Last FundingOct 27, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.